[{"address1": "Science Park", "address2": "2 Snunit St. POB 455", "city": "Karmiel", "zip": "2161401", "country": "Israel", "phone": "972 4 902 8100", "fax": "972 4 988 9489", "website": "https://www.protalix.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Funda\u00e7\u00e3o Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.", "fullTimeEmployees": 208, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dror  Bashan", "age": 56, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 1376823, "exercisedValue": 0, "unexercisedValue": 175781}, {"maxAge": 1, "name": "Mr. Eyal  Rubin M.B.A.", "age": 47, "title": "Senior VP, CFO, Treasurer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 686779, "exercisedValue": 0, "unexercisedValue": 82031}, {"maxAge": 1, "name": "Mr. Yaron  Naos", "age": 59, "title": "Senior Vice President of Operations", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 513819, "exercisedValue": 0, "unexercisedValue": 79688}, {"maxAge": 1, "name": "Ms. Yael  Fellous", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.01, "open": 1.02, "dayLow": 1.01, "dayHigh": 1.05, "regularMarketPreviousClose": 1.01, "regularMarketOpen": 1.02, "regularMarketDayLow": 1.01, "regularMarketDayHigh": 1.05, "beta": 0.694, "forwardPE": 1.6451613, "volume": 74062, "regularMarketVolume": 74062, "averageVolume": 398832, "averageVolume10days": 191670, "averageDailyVolume10Day": 191670, "bid": 1.0, "ask": 1.03, "bidSize": 1000, "askSize": 900, "marketCap": 75013560, "fiftyTwoWeekLow": 0.82, "fiftyTwoWeekHigh": 1.9, "priceToSalesTrailing12Months": 1.9712917, "fiftyDayAverage": 1.0624, "twoHundredDayAverage": 1.3079, "currency": "USD", "enterpriseValue": 55401100, "profitMargins": -0.38615, "floatShares": 54750315, "sharesOutstanding": 73542704, "sharesShort": 3503685, "sharesShortPriorMonth": 3630093, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0476, "heldPercentInsiders": 0.14534001, "heldPercentInstitutions": 0.077360004, "shortRatio": 18.34, "shortPercentOfFloat": 0.0498, "bookValue": 0.39, "priceToBook": 2.6153846, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -14694000, "trailingEps": -0.23, "forwardEps": 0.62, "pegRatio": 1.82, "lastSplitFactor": "1:10", "lastSplitDate": 1576800000, "enterpriseToRevenue": 1.456, "enterpriseToEbitda": -4.096, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "PLX", "underlyingSymbol": "PLX", "shortName": "Protalix BioTherapeutics, Inc. ", "longName": "Protalix BioTherapeutics, Inc.", "firstTradeDateEpochUtc": 895239000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "febb5b62-804d-3e32-9700-f4c9c8179dca", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.02, "targetHighPrice": 14.0, "targetLowPrice": 10.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 45029000, "totalCashPerShare": 0.612, "ebitda": -13526000, "totalDebt": 26152000, "quickRatio": 0.951, "currentRatio": 1.335, "totalRevenue": 38053000, "debtToEquity": 91.501, "revenuePerShare": 0.522, "returnOnAssets": -0.1027, "returnOnEquity": -0.43485, "freeCashflow": 1315375, "operatingCashflow": -2715000, "revenueGrowth": -0.616, "grossMargins": 0.32181, "ebitdaMargins": -0.35544997, "operatingMargins": -0.18011999, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]